In vitro drug responses in primary and metastatic colorectal cancers

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 1, 2011, Pages 70-78

  Mechetner, Eugene ^a   Brnner, Nils ^b   Parker, Ricardo J ^a,b  

^a Exiqon Diagnostics   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colonic disorders; Oncology basic; Oncology clinical

Indexed keywords

CARMUSTINE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; TUMOR BIOPSY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 78651367218     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.510573     Document Type: Article

References (30)

1. Steele GD Jr. The national cancer data base report on colorectal cancer. Cancer 1994;74:1979-89.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
4. Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Orga-nisation for Research and Treatment of Cancer Gastrointes-tinal Group Study 40986. J Clin Oncol 2005;23:4811-14.
5. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001;13:275-86.
6. Tournigand C, André T, Achille E, Liedo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22: 229-37.
7. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-6.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Hein W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
9. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Fign A, Wons R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colo-rectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19.
10. Alberts D, Salmon SE, Chen GH-S, Moon TE, Young L, Surwit EA. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chem Pharmacol 1981;6:253-64.
11. Tanigawa N, Morimoto H, Dohmae N, Shimomatsuya T, Takahashi K, Muraoka R. In vitro growth ability and che-mosensitivity of gastric and colorectal cancer cells assessed with the human tumour clonogenic assay and the thymidine incorporation assay. Eur J Cancer 1992;28:31-4.
12. Kern DM, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;82:582-8.
13. Fruehauf JP, Bosanquet AG. In vitro determination of drug response: a discussion of clinical applications. Princ Pract Oncol Updat 1993;7:1-17.
14. Mehta R, Bornstein R, Yu I-R, Parker RJ, McLaren CE, Nguyen KP, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 2001;66:225-37.
15. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002;87:8-16.
16. Haroun RI, Clatterbuck RE, Gibbons C, Burger PC, Parker RJ, Fruehof JP, et al. Extreme drug resistance in primary brain tumors: in vitro analysis of64 resection speci-mens. J Neurooncol 2002;58:115-23.
17. Liozzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003; 189:1301-7.
18. Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. A prospective study of the predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 2004;66:365-75.
19. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, et al. Levels of multidrug resistance (MDR1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998;4:389-98.
20. D'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalence of in vitro extreme chemotherapy resistance in resected non-small-cell lung cancer. Ann Thorac Surg 2006; 81: 440-7.
21. D'Amato TA, Pettiford BL, Schubert MJ, Parker R, Ricketts WA, Luktich JD, et al. Survival among patients with platinum resistance, locally advanced non-small cell cancer treated with platinum-based systemic therapy. Ann Surg Oncol 2009; 16: 2848-55.
22. Verleye L, Coens C, Amant F, et al. Extreme drug resistance for carboplatin predicts resistance to first-line therapy in advanced-stage ovarian cancer: results from the EORTC-GCG/NCIC-CTG neoadjuvant trial. Communication at the 12th Biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, 25-28 October 2008. Abstr 1422.
23. Dept Health Human Services, Health Insurance Portability and Accountability Act of 1996 (HIPAA), 45 CFR Part 160.103: In General administrative requirements, Subpart A; and 45 CFR Parts 164.512 and 164.514: In Security and privacy, Subpart E, Prepared: 20 February 2003. Available online at: (www.wedi.org/snip/public/articles/45CFR160&164.pdf).
24. Köhne C-H, Bruce C, Folprecht G, Audisio R. Role of new agents in the treatment of colorectal cancer. Surg Oncol 2004;13:75-81. (Pubitemid 39572081)
25. de Gramont A, Figer A, Seymour M, Homeren M, Hrnissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
26. Saltz LB, Douillard J-V, Pirotta N, Alaki M, Gruia G, Awad L, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6:81-91.
27. Goldberg R. Advances in the treatment of metastatic colo-rectal cancer. Oncologist 2005;10:40-8.
28. Saunders M, Iveson T. Management of advanced colorectal cancer: state ofthe art. Br J Cancer 2006; 95: 131-8.
29. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevicizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperation Ocology Group Study E3200. J Clin Oncol 2007;25:1539-44.
30. Jaffer A, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal cancer. Invest New Drugs 1998;16:175-7.